Mechanisms of the development of androgen independence in prostate cancer

被引:160
作者
So, A [1 ]
Gleave, M [1 ]
Hurtado-Col, A [1 ]
Nelson, C [1 ]
机构
[1] Univ British Columbia, Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada
关键词
prostate cancer; androgen independence; hormone-refractory prostate cancer;
D O I
10.1007/s00345-004-0473-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The effectiveness of androgen ablation in the management of advanced prostate cancer is of limited duration, with the median length of response being only 18-24 months. The transition of the prostate cancer cell to an androgen independent phenotype is a complex process that involves selection and outgrowth of preexisting clones of androgen-independent cells (clonal selection) as well as adaptive up-regulation of genes that help the cancer cells survive and grow after androgen ablation (adaptation). These two mechanisms share an important pre-requisite characteristic: prostate cancers are heterogeneous tumours comprised of various sub-populations of cells that respond differently to androgen withdrawal therapy. This tumour heterogeneity may reflect either a multifocal origin, adaptation to environmental stimuli, and/or genetic instability of the initial cancer. This review will reexamine the different mechanisms that enable prostate cancer cells to proliferate in an androgen depleted environment.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 96 条
[1]  
Bakin RE, 2003, CANCER RES, V63, P1981
[2]  
Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO
[3]  
2-2
[4]   Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer [J].
Brown, RSD ;
Edwards, J ;
Dogan, A ;
Payne, H ;
Harland, SJ ;
Bartlett, JMS ;
Masters, JRW .
JOURNAL OF PATHOLOGY, 2002, 198 (02) :237-244
[5]   Hormone therapy failure in human prostate cancer:: Analysis by complementary DNA and issue microarrays [J].
Bubendorf, L ;
Kolmer, M ;
Kononen, J ;
Koivisto, P ;
Mousses, S ;
Chen, YD ;
Mahlamäki, E ;
Schraml, P ;
Moch, H ;
Willi, N ;
Elkahloun, AG ;
Pretlow, TG ;
Gasser, TC ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) :1758-1764
[6]  
Calero M, 2000, MICROSC RES TECHNIQ, V50, P305, DOI 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO
[7]  
2-L
[8]   Direct transactivation of the anti-apoptotic gene apolipoprotein J (Clusterin) by B-MYB [J].
Cervellera, M ;
Raschella, G ;
Santilli, G ;
Tanno, B ;
Ventura, A ;
Mancini, C ;
Sevignani, C ;
Calabretta, B ;
Sala, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :21055-21060
[9]   Bcl-2 antisense therapy in B-cell malignant proliferative disorders [J].
Chanan-Khan A. ;
Czuczman M.S. .
Current Treatment Options in Oncology, 2004, 5 (4) :261-267
[10]   Molecular determinants of resistance to antiandrogen therapy [J].
Chen, CD ;
Welsbie, DS ;
Tran, C ;
Baek, SH ;
Chen, R ;
Vessella, R ;
Rosenfeld, MG ;
Sawyers, CL .
NATURE MEDICINE, 2004, 10 (01) :33-39